Alnylam Pharmaceuticals ALNY Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.71B+65.2% | $2.25B+23.0% | $1.83B+76.2% | $1.04B+22.9% | ||
| $677.17M+121% | $306.51M+14.3% | $268.22M+91.3% | $140.17M+21.9% | ||
| $3.04B+56.4% | $1.94B+24.5% | $1.56B+73.9% | $897.24M+23.0% | ||
| 81.8%-4.6pp | 86.4%+1.0pp | 85.3%-1.2pp | 86.5%+0.1pp | ||
| $1.32B+17.2% | $1.13B+12.1% | $1B+13.7% | $883.02M+11.5% | ||
| $1.21B+24.1% | $975.53M+22.6% | $795.65M+3.2% | $770.66M+24.2% | ||
| $3.21B+32.5% | $2.43B+14.9% | $2.11B+15.8% | $1.82B+17.4% | ||
| $501.58M+384% | -$176.89M+37.3% | -$282.18M+64.1% | -$785.07M-10.8% | ||
| 13.5%+21.4pp | -7.9%+7.6pp | -15.4%+60.2pp | -75.7%+8.3pp | ||
| $208.35M+46.9% | $141.86M+17.0% | $121.22M-22.3% | $155.97M+9.1% | ||
| -$214.07M-6.8% | -$200.49M-32.5% | -$151.34M+55.7% | -$341.92M-138% | ||
| $287.5M+176% | -$377.38M+13.0% | -$433.52M+61.5% | -$1.13B-32.3% | ||
| —— | -$99.22M-1,575% | $6.73M+61.5% | $4.16M— | ||
| $278.1M+200% | -$278.16M+36.8% | -$440.24M+61.1% | -$1.13B-32.6% | ||
| 7.5%+19.9pp | -12.4%+11.7pp | -24.1%+85.0pp | -109%-8.0pp | ||
| $2.01+193% | -$2.17+38.9% | -$3.55+61.8% | -$9.29-29.0% | ||
| $557.24M+564% | -$120.22M+47.3% | -$228.12M+69.2% | -$740.6M-12.0% | ||
| 15%+20.4pp | -5.3%+7.1pp | -12.5%+58.9pp | -71.4%+6.9pp | ||
| $501.58M+384% | -$176.89M+37.3% | -$282.18M+64.1% | -$785.07M-10.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
- Is Alnylam Pharmaceuticals profitable?
- Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
- What are Alnylam Pharmaceuticals's profit margins?
- Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
- What is Alnylam Pharmaceuticals's earnings per share?
- Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
- Where does Alnylam Pharmaceuticals's income statement data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
